@article{a6cc229692064d228f0d42cd8e6904fa,
title = "May measurement month 2018: A pragmatic global screening campaign to raise awareness of blood pressure by the international society of hypertension",
abstract = "Aims: Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results: Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and environmental factors. Hypertension was defined as a systolic BP ≥140mmHg or diastolic BP ≥90 mmHg, or taking antihypertensive medication. In total, 74.9% of screenees provided three BP readings. Multiple imputation using chained equations was used to impute missing readings. 1 504 963 individuals (mean age 45.3 years; 52.4% female) were screened. After multiple imputation, 502 079 (33.4%) individuals had hypertension, of whom 59.5% were aware of their diagnosis and 55.3% were taking antihypertensive medication. Of those on medication, 60.0% were controlled and of all hypertensives, 33.2% were controlled. We detected 224 285 individuals with untreated hypertension and 111 214 individuals with inadequately treated (systolic BP ≥ 140mmHg or diastolic BP ≥ 90 mmHg) hypertension. Conclusion: May Measurement Month expanded significantly compared with 2017, including more participants in more countries. The campaign identified over 335 000 adults with untreated or inadequately treated hypertension. In the absence of systematic screening programmes, MMM was effective at raising awareness at least among these individuals at risk.",
keywords = "Blood pressure, Control, Global, Hypertension, Screening, Treatment",
author = "Thomas Beaney and Burrell, {Louise M.} and Castillo, {Rafael R.} and Charchar, {Fadi J.} and Suzie Cro and Albertino Damasceno and Ruan Kruger and Nilsson, {Peter M.} and Dorairaj Prabhakaran and Ramirez, {Agustin J.} and Schlaich, {Markus P.} and Schutte, {Aletta E.} and Maciej Tomaszewski and Rhian Touyz and Wang, {Ji Guang} and Weber, {Michael A.} and Poulter, {Neil R.} and Genc Burazeri and Gentiana Qirjako and Enver Roshi and Rudina Cunashi and Fernandes, {Mario J.C.C.} and Pereira, {Savarino S.Vict{\'o}ria} and Neto, {Marisa F.M.P.} and Oliveira, {Pombalino N.M.} and Feij{\~a}o, {Ana C.G.} and Yamila Cerniello and Marin, {Marcos J.} and Vasquez, {Fortunato Garcia} and Espeche, {Walter G.} and Diego Stisman and Fuentes, {In{\'e}s A.} and Zilberman, {Juith M.} and Pablo Rodriguez and Babinyan, {Kamsar Yu} and Engibaryan, {Anna H.} and Avagyan, {Avag M.} and Minasyan, {Arsen A.} and Gevorkyan, {Ani T.} and Revathy Carnagarin and Carrington, {Melinda J.} and Sharman, {James E.} and Rebecca Lee and Sabine Perl and Ella Niederl and Malik, {Fazila Tun Nesa} and Choudhury, {Sohel R.} and {Al Mamun}, {Mohammad A.} and Mir Ishraquzzaman and Ala'a Alkerwi and {MMM Investigators} and Manon Gantenbein",
note = "Funding Information: Conflict of interest: T.B. and L.M.B. have nothing to declare. R.R.C. reports other from Boehringer Ingelheim, other from Servier, other from Menarini, other from Lri Thermapharma, other from Abbott, personal fees from AstraZeneca, personal fees from UAP Pharma, personal fees from Torrent, personal fees from Stada, outside the submitted work. F.J.C., S.C., A.D., R.K., P.M.N., D.P., and A.J.R. have nothing to declare. M.P.S. reports non-financial support from OMRON, non-financial support from A&D, during the conduct of the study; personal fees from Medtronic, personal fees from Abbott, personal fees from Novartis, grants from Boehringer ingelheim, outside the submitted work. A.E.S. has received personal fees from Servier, Abbott, Novartis and Omron and non-financial support during the conduct of a study from Abbott. M.T. and R.T have nothing to declare. J.-G.W. reports non-financial support from Omron, during the conduct of the study; grants from Bayer, MSD, and Philips, personal fees from Daiichi-Sankyo and Takeda, outside the submitted work. M.A.W. reports personal fees from Ablative Solutions, personal fees from Astellas, personal fees from Boston Scientific, personal fees from Johnson & Johnson, personal fees from Medtronic, personal fees from Omron, personal fees from Recor, outside the submitted work. N.R.P. has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier), research projects and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi and Pfizer). He holds no stocks and shares in any such companies. Publisher Copyright: {\textcopyright} The Author(s) 2019.",
year = "2019",
month = jul,
day = "1",
doi = "10.1093/eurheartj/ehz300",
language = "English",
volume = "40",
pages = "2006--2017",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "25",
}